Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG9C4I)

• Drug Name: Galidesivir Drug Info
• Synonyms: 1EL1K52SH1; BCX 4430; BCX 4430 HCl; BCX4430; CS-3778; Galidesivir (hydrochloride); HY-18649; Immucillin-A; SB16943; SCHEMBL4838048; UNII-1EL1K52SH1

Indication

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1	[1]
Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[2]
Severe acute respiratory syndrome (SARS)	1D65	Preclinical	[2]

• Therapeutic Class: Antiviral Agents
• Cross-matching ID:
  PubChem CID: 10445549
  CAS Number: CAS 249503-25-1
  TTD Drug ID: DMG9C4I

Molecule-Related Drug Atlas

Drug(s) Targeting MERS-CoV RNA-directed RNA polymerase (RdRp)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[2]
Remdesivir	DMBFZ6L	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved	[4]
PMID31244113-compound-2c	DMZJWON	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[5]
PMID26048809-compound2	DMFNS7U	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[2]
Amarylline	DML9W2V	Middle East Respiratory Syndrome (MERS)	1D64	Investigative	[6]

Drug(s) Targeting SARS-CoV RNA-directed RNA polymerase (RdRp)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[2]
Remdesivir	DMBFZ6L	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved	[4]
PMID31244113-compound-2c	DMZJWON	Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[5]

Drug(s) Targeting COVID-19 RNA-directed RNA polymerase (RdRp)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Remdesivir	DMBFZ6L	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved	[7]
Remdesivir	DMBFZ6L	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved	[8]
Penciclovir	DMOUMDV	Herpes simplex labialis	1F00.01	Approved	[7]
Anidulafungin	DM8QM5U	Aspergillosis	1F20	Approved	[9]
Favipiravir	DMBZ27L	Influenza virus infection	1E30-1E32	Registered	[10]
Suramin	DMTOUY9	African trypanosomiasis	1F51	Phase 1	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
COVID-19 RNA-directed RNA polymerase (RdRp)	TTV1095	R1AB_SARS2 (4393-5324)	Blocker	[3]
MERS-CoV RNA-directed RNA polymerase (RdRp)	TTOA6YT	R1AB_CVEMC (4378-5310)	Inhibitor	[2]
SARS-CoV RNA-directed RNA polymerase (RdRp)	TTKXI53	R1AB_CVHSA (4370-5301)	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03891420) A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19. U.S. National Institutes of Health.
• [2] Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
• [3] BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19
• [4] Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222.
• [5] Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues. J Med Chem. 2019 Jul 11;62(13):6346-6362.
• [6] Lycorine: A prospective natural lead for anticancer drug discovery. Biomed Pharmacother. 2018 Nov;107:615-624.
• [7] Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [9] Suramin, Penciclovir and Anidulafungin bind nsp12, which governs the RNA-dependent-RNA polymerase activity of SARS-CoV-2, with higher interaction energy than Remdesivir, indicating potential in the treatment of Covid-19 infection. April.21.2020. Doi: 10.31219/osf.io/urxwh
• [10] Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. Posted April 15, 2020.